Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis

Islam, Asiful; Alam, Fahmida; Cavestro, Cinzia; Cornelia, Călcîi; Sasongko, Teguh Haryo; Levy, Roger A.; Gan, Siew Hua

doi:10.1016/j.autrev.2018.01.025

Cited by 19 publications

(13 citation statements)

References 71 publications

(116 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In epilepsy patients, without co-morbidities, aPL were distributed as follows: aCL 28.7% vs. 8.1% in HCs (OR: 5.2, 95% CI: 3.2-8.3, p < 0.01; I 2 ¼44%, p ¼ 0.04), more in paediatrics, also more in partial vs. generalized epilepsy, and in Asian vs. Europeans; ab2GPI (screened in 7/14 studies): 11.8% vs. 2.8% in HCs (OR: 3, 95% CI: 1.1-8.1, p ¼ 0.04; I 2 ¼35%, p ¼ 0.16), and was significant in pediatric and African population with epilepsies. 20 Another systematic review about aPL and dementia in the general population included 32 studies, some observational. The aCL prevalence ranged from 5.9% to 31.1% in the general population, 4 studies investigated the prevalence of aPL in patients with cognitive impairment/dementia (small samples, inconsistent aPL profiling, and heterogeneous definition of cognitive damage): overall the prevalence of aPL ranged from 6% to 56.6% in vascular dementia, and aCL, the most tested, was found to be more prevalent and with higher titers in patients with dementia vs. HCs.…”

Section: Neurological Involvement Recommendations and Overall Quality Of Evidencementioning

confidence: 99%

16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome

Sciascia

Radin

Cecchi

et al. 2021

Lupus

View full text Add to dashboard Cite

The objectives of the 16th International Congress on Antiphospholipid Antibodies (aPL) Task Force on Clinical Manifestations of Antiphospholipid Syndrome (APS) were to critically analyze: a) the definition of “APS”; b) the current knowledge on non-traditional manifestations associated with aPL; and c) the risk stratification strategies in aPL-positive patients. The quality of evidence was assessed by the GRADE system. The task force concluded that: a) APS does not have a uniform definition given the heterogeneity of the clinical presentations and different aPL profiles; b) current literature supports the role for aPL testing in cases of thrombocytopenia and recurrent cardiac events but are limited by vast heterogeneity, providing an overall low-to-very low level of evidence; and c) risk stratification strategies in aPL-positive patients, such as aPL-Score and Global APS Score, can be useful in clinical practice. International multicenter studies are still highly needed to improve the quality of available evidence and consequently the strength of future recommendations.

show abstract

Section: Neurological Involvement Recommendations and Overall Quality Of Evidencementioning

confidence: 99%

16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome

Sciascia

Radin

Cecchi

et al. 2021

Lupus

View full text Add to dashboard Cite

show abstract

“…A few articles studied ACA in other diseases, including epilepsy, preeclampsia, chorea, Budd-Chiari syndrome, and chronic pancreatitis (especially for autoimmune pancreatitis). There might be an autoimmune-mediated pathogenesis, especially via ACA, in the onset of these diseases [53–57].…”

Section: The Clinical Significance Of Aca Laboratory Detectionmentioning

confidence: 99%

Advances in the Research on Anticardiolipin Antibody

Wang

Zhang

et al. 2019

Journal of Immunology Research

View full text Add to dashboard Cite

Anticardiolipin antibody (ACA) is a kind of autoantibody and is one of the antiphospholipid antibodies (aPLs). Phospholipids with a negative charge on platelets and endothelial cell membranes are ACA target antigens. ACA is common in systemic lupus erythematosus and other autoimmune diseases and is closely associated with thrombosis, thrombocytopenia, and spontaneous abortion. In 1983, Harris established a method for detecting ACA, and research on the antibody has gained worldwide attention and has developed rapidly. For this review, we browsed articles that cover most of the ACA-related studies in the last 25 years and extracted influential ideas and conclusions in this field.

show abstract

“…Several previous meta-analysis studies have found an association between autoimmune diseases and epilepsy; 5,38 however, the relationship between specific autoimmune diseases and epilepsy is still not well understood. Here we included five high quality studies with NOS > 7 [32][33][34][35]37 and one medium quality study with NOS = 5.…”

Section: Discussionmentioning

confidence: 99%

Risk of epilepsy in rheumatoid arthritis: a meta-analysis of population based studies and bioinformatics analysis

Zhao

Xie

et al. 2020

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Background: An increasing number of studies support an association between rheumatoid arthritis (RA) and brain disorders. This study aims to determine the association between RA and epilepsy. Methods: A comprehensive search of databases in both English and Chinese was performed. Data from the selected studies were extracted and analyzed independently by two authors. Genes associated with epilepsy and RA were also collected and analyzed. Results: We included six nationwide population based studies ( n = 7,094,113 cases in total) for the meta-analysis. The risk of epilepsy was increased in RA patients [risk ratio (RR) = 1.601; 95% confidence interval (CI): 1.089–2.354; p = 0.017; n = 3,803,535 cases] and children born to mothers with RA (RR = 1.475; 95% CI: 1.333–1.633; p < 0.001, n = 3,290,578 cases). Subgroup analysis and meta-regression showed the RR of epilepsy in RA was negatively correlated with age. Furthermore, we found that 433 identified genes in a coexpression network from the hippocampi of 129 epileptic patients were enriched in the RA and related Kyoto Encyclopedia of Genes and Genomes pathways, while 13 genes (mainly related to inflammatory cytokines and chemokines) were identified as potential key genes bridging the RA and epilepsy. Conclusions: Our study, utilizing meta-analysis and bioinformatical data, highlights a close association between epilepsy and RA. Further studies are still warranted to expand these findings, especially for a population that is exposed to RA during fetal and childhood periods.

show abstract

Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis

Cited by 19 publications

References 71 publications

16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome

16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome

Advances in the Research on Anticardiolipin Antibody

Risk of epilepsy in rheumatoid arthritis: a meta-analysis of population based studies and bioinformatics analysis

Contact Info

Product

Resources

About